Standard
Reply to : “Comment on ‘Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'”. / Egeberg, Alexander; Bryld, Lars Erik; Skov, Lone.
I:
Journal of the American Academy of Dermatology, Bind 85, Nr. 6, 2021, s. e379.
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Harvard
Egeberg, A, Bryld, LE & Skov, L 2021, '
Reply to: “Comment on ‘Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'”',
Journal of the American Academy of Dermatology, bind 85, nr. 6, s. e379.
https://doi.org/10.1016/j.jaad.2019.05.082
APA
Egeberg, A., Bryld, L. E., & Skov, L. (2021).
Reply to: “Comment on ‘Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'”.
Journal of the American Academy of Dermatology,
85(6), e379.
https://doi.org/10.1016/j.jaad.2019.05.082
Vancouver
Egeberg A, Bryld LE, Skov L.
Reply to: “Comment on ‘Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'”.
Journal of the American Academy of Dermatology. 2021;85(6):e379.
https://doi.org/10.1016/j.jaad.2019.05.082
Author
Egeberg, Alexander ; Bryld, Lars Erik ; Skov, Lone. / Reply to : “Comment on ‘Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'”. I: Journal of the American Academy of Dermatology. 2021 ; Bind 85, Nr. 6. s. e379.
Bibtex
@article{7db87e5463f8432f8f91b4c299ad2ae6,
title = "Reply to: “Comment on {\textquoteleft}Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'”",
author = "Alexander Egeberg and Bryld, {Lars Erik} and Lone Skov",
note = "Funding Information: Disclosure: Dr Egeberg has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Samsung Bioepis, Bristol-Meyers Squibb, UCB, Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. Dr Skov has been a paid speaker for Pfizer, AbbVie, Eli Lilly, Novartis, and LEO Pharma; has been a consultant or served on advisory boards with Pfizer, AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, and Sanofi; has served as an investigator for Pfizer, AbbVie, Eli Lilly, Novartis, Amgen, Regeneron, and LEO Pharma; and received research and educational grants from Pfizer, AbbVie, Novartis, Sanofi, Janssen Cilag, and Leo Pharma. The authors do not have equity in pharmaceutical companies. Funding sources: None. Funding Information: Disclosure: Dr Egeberg has received research funding from Pfizer , Eli Lilly , the Danish National Psoriasis Foundation , and the Kgl Hofbundtmager Aage Bang Foundation and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Samsung Bioepis, Bristol-Meyers Squibb, UCB, Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. Dr Skov has been a paid speaker for Pfizer, AbbVie, Eli Lilly, Novartis, and LEO Pharma; has been a consultant or served on advisory boards with Pfizer, AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, and Sanofi; has served as an investigator for Pfizer, AbbVie, Eli Lilly, Novartis, Amgen, Regeneron, and LEO Pharma; and received research and educational grants from Pfizer , AbbVie , Novartis , Sanofi , Janssen Cilag , and Leo Pharma . The authors do not have equity in pharmaceutical companies. ",
year = "2021",
doi = "10.1016/j.jaad.2019.05.082",
language = "English",
volume = "85",
pages = "e379",
journal = "American Academy of Dermatology. Journal",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "6",
}
RIS
TY - JOUR
T1 - Reply to
T2 - “Comment on ‘Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'”
AU - Egeberg, Alexander
AU - Bryld, Lars Erik
AU - Skov, Lone
N1 - Funding Information:
Disclosure: Dr Egeberg has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Samsung Bioepis, Bristol-Meyers Squibb, UCB, Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. Dr Skov has been a paid speaker for Pfizer, AbbVie, Eli Lilly, Novartis, and LEO Pharma; has been a consultant or served on advisory boards with Pfizer, AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, and Sanofi; has served as an investigator for Pfizer, AbbVie, Eli Lilly, Novartis, Amgen, Regeneron, and LEO Pharma; and received research and educational grants from Pfizer, AbbVie, Novartis, Sanofi, Janssen Cilag, and Leo Pharma. The authors do not have equity in pharmaceutical companies. Funding sources: None.
Funding Information:
Disclosure: Dr Egeberg has received research funding from Pfizer , Eli Lilly , the Danish National Psoriasis Foundation , and the Kgl Hofbundtmager Aage Bang Foundation and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Samsung Bioepis, Bristol-Meyers Squibb, UCB, Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. Dr Skov has been a paid speaker for Pfizer, AbbVie, Eli Lilly, Novartis, and LEO Pharma; has been a consultant or served on advisory boards with Pfizer, AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, and Sanofi; has served as an investigator for Pfizer, AbbVie, Eli Lilly, Novartis, Amgen, Regeneron, and LEO Pharma; and received research and educational grants from Pfizer , AbbVie , Novartis , Sanofi , Janssen Cilag , and Leo Pharma . The authors do not have equity in pharmaceutical companies.
PY - 2021
Y1 - 2021
U2 - 10.1016/j.jaad.2019.05.082
DO - 10.1016/j.jaad.2019.05.082
M3 - Letter
C2 - 31170436
AN - SCOPUS:85078728283
VL - 85
SP - e379
JO - American Academy of Dermatology. Journal
JF - American Academy of Dermatology. Journal
SN - 0190-9622
IS - 6
ER -
